ASX Mkt. Sensitive<p>Immuron ( <a href="https://mastodon-grafa.social/tags/IMC" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>IMC</span></a> ) has released " Immuron Travelan highest sales in history " on Thu 10 Apr at 11:20 AEST <a href="https://mastodon-grafa.social/tags/government" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>government</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/Strategy" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Strategy</span></a> <br><a href="https://grafa.com/asset/immuron-ltd-2491-imc.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=imc.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/immuron-ltd-24</span><span class="invisible">91-imc.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=imc.asx</span></a></p>
Recent searches
No recent searches
Search options
Only available when logged in.
med-mastodon.com is one of the many independent Mastodon servers you can use to participate in the fediverse.
Medical community on Mastodon
Administered by:
Server stats:
431active users
med-mastodon.com: About · Profiles directory · Privacy policy
Mastodon: About · Get the app · Keyboard shortcuts · View source code · v4.3.7
#clinicaltrials
11 posts · 7 participants · 2 posts today
ASX Mkt. Sensitive<p>Alterity Therapeutics ( <a href="https://mastodon-grafa.social/tags/ATH" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ATH</span></a> ) has released " Alterity Presents Encouraging New Phase 2 Data in MSA " on Thu 10 Apr at 10:11 AEST <a href="https://mastodon-grafa.social/tags/today" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>today</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Gold" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Gold</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <br><a href="https://grafa.com/asset/alterity-therapeutics-ltd-641-ath.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=ath.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/alterity-thera</span><span class="invisible">peutics-ltd-641-ath.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=ath.asx</span></a></p>
ASX Mkt. Sensitive<p>Tryptamine Therapeutics Limited ( <a href="https://mastodon-grafa.social/tags/TYP" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>TYP</span></a> ) has released " TRP-8803 BED trial to commence with Swinburne this quarter " on Thu 10 Apr at 09:15 AEST <a href="https://mastodon-grafa.social/tags/Mining" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Mining</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/News" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>News</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <br><a href="https://grafa.com/asset/tryptamine-therapeutics-limited-26766-typ.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=typ.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/tryptamine-the</span><span class="invisible">rapeutics-limited-26766-typ.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=typ.asx</span></a></p>
ASX Mkt. Sensitive<p>PYC Therapeutics ( <a href="https://mastodon-grafa.social/tags/PYC" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>PYC</span></a> ) has released " First Subject Dosed in PKD Clinical Trial " on Thu 10 Apr at 08:45 AEST <a href="https://mastodon-grafa.social/tags/today" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>today</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/live" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>live</span></a> <br><a href="https://grafa.com/asset/pyc-therapeutics-ltd-3821-pyc.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=pyc.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/pyc-therapeuti</span><span class="invisible">cs-ltd-3821-pyc.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=pyc.asx</span></a></p>
Benjamin Carr, Ph.D. 👨🏻💻🧬<p>What <a href="https://hachyderm.io/tags/NIH" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>NIH</span></a> <a href="https://hachyderm.io/tags/Layoffs" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Layoffs</span></a> Mean for <a href="https://hachyderm.io/tags/Cancer" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Cancer</span></a> Patients<br>In the rush of headlines about budgets and restructuring, it’s easy to miss what’s really at stake. But working in cancer innovation and advocacy: when we delay <a href="https://hachyderm.io/tags/science" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>science</span></a>, we delay survival. When we dismantle <a href="https://hachyderm.io/tags/research" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>research</span></a> infrastructure, people <a href="https://hachyderm.io/tags/die" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>die</span></a> waiting. Thousands at <a href="https://hachyderm.io/tags/NIH" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>NIH</span></a> and <a href="https://hachyderm.io/tags/HHS" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>HHS</span></a> were laid off. These were the people running <a href="https://hachyderm.io/tags/clinicaltrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>clinicaltrials</span></a>, developing new treatment strategies, and pushing promising therapies toward approval.<br><a href="https://scilight.substack.com/p/what-nih-layoffs-mean-for-cancer" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">scilight.substack.com/p/what-n</span><span class="invisible">ih-layoffs-mean-for-cancer</span></a></p>
ASX Mkt. Sensitive<p>IDT Australia ( <a href="https://mastodon-grafa.social/tags/IDT" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>IDT</span></a> ) has released " New $3.2M Contract Supports Australia's Largest API Plant " on Wed 09 Apr at 09:40 AEST <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/Strategy" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Strategy</span></a> <a href="https://mastodon-grafa.social/tags/ltd" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ltd</span></a> <br><a href="https://grafa.com/asset/idt-australia-ltd-7707-idt.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=idt.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/idt-australia-</span><span class="invisible">ltd-7707-idt.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=idt.asx</span></a></p>
ASX Mkt. Sensitive<p>Orthocell ( <a href="https://mastodon-grafa.social/tags/OCC" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>OCC</span></a> ) has released " Regulatory Approval for Striate in US$65M Brazilian Market " on Wed 09 Apr at 09:19 AEST <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/Strategy" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Strategy</span></a> <a href="https://mastodon-grafa.social/tags/live" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>live</span></a> <br><a href="https://grafa.com/asset/orthocell-ltd-177-occ.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=occ.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/orthocell-ltd-</span><span class="invisible">177-occ.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=occ.asx</span></a></p>
ASX Mkt. Sensitive<p>Nyrada ( <a href="https://mastodon-grafa.social/tags/NYR" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>NYR</span></a> ) has released " Phase I Clinical Trial Dosing Update No 1 " on Wed 09 Apr at 08:22 AEST <a href="https://mastodon-grafa.social/tags/today" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>today</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/live" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>live</span></a> <br><a href="https://grafa.com/asset/nyrada-inc-3430-nyr.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=nyr.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/nyrada-inc-343</span><span class="invisible">0-nyr.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=nyr.asx</span></a></p>
ASX Mkt. Sensitive<p>Nyrada ( <a href="https://mastodon-grafa.social/tags/NYR" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>NYR</span></a> ) has released " Significant Neuroprotection in Traumatic Brain Injury Study " on Mon 07 Apr at 08:27 AEST <a href="https://mastodon-grafa.social/tags/today" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>today</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/ASX" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ASX</span></a> <br><a href="https://grafa.com/asset/nyrada-inc-3430-nyr.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=nyr.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/nyrada-inc-343</span><span class="invisible">0-nyr.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=nyr.asx</span></a></p>
Bruno Amaral<p>I have an Excel file with over 5000 <a href="https://mastodon.social/tags/clinicaltrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>clinicaltrials</span></a> for <a href="https://mastodon.social/tags/MultipleSclerosis" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>MultipleSclerosis</span></a>. It's yours if you want it, for free. You can find the data here <a href="https://gregory-ms.com/trials/" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="">gregory-ms.com/trials/</span><span class="invisible"></span></a> <a href="https://mastodon.social/tags/MSChat" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>MSChat</span></a></p>
ResearchBuzz: Firehose<p>National Library of Medicine: ClinicalTrials.gov: A 25-Year Journey to a Half-Million Registered Studies. “Since its launch in 2000, ClinicalTrials.gov has been a reliable registry and results database for clinical trials from the National Institutes of Health and NLM. In 2005, ClinicalTrials.gov broadened its reach to include information on clinical studies around the world, covering a wide […]</p><p><a href="https://rbfirehose.com/2025/04/05/clinicaltrials-gov-a-25-year-journey-to-a-half-million-registered-studies-national-library-of-medicine/" class="" rel="nofollow noopener noreferrer" target="_blank">https://rbfirehose.com/2025/04/05/clinicaltrials-gov-a-25-year-journey-to-a-half-million-registered-studies-national-library-of-medicine/</a></p>
ASX Mkt. Sensitive<p>Mesoblast ( <a href="https://mastodon-grafa.social/tags/MSB" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>MSB</span></a> ) has released " Mesoblast Cell Therapy Products Not Subject to U.S. Tariffs " on Fri 04 Apr at 09:33 AEST <a href="https://mastodon-grafa.social/tags/today" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>today</span></a> <a href="https://mastodon-grafa.social/tags/government" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>government</span></a> <a href="https://mastodon-grafa.social/tags/China" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>China</span></a> <a href="https://mastodon-grafa.social/tags/UnitedStates" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>UnitedStates</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <br><a href="https://grafa.com/asset/mesoblast-ltd-3198-msb.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=msb.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/mesoblast-ltd-</span><span class="invisible">3198-msb.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=msb.asx</span></a></p>
ASX Mkt. Sensitive<p>Orthocell ( <a href="https://mastodon-grafa.social/tags/OCC" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>OCC</span></a> ) has released " Remplir Cleared to Commence Sales in US$1.6B US Market " on Fri 04 Apr at 09:23 AEST <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/Strategy" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Strategy</span></a> <a href="https://mastodon-grafa.social/tags/live" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>live</span></a> <br><a href="https://grafa.com/asset/orthocell-ltd-177-occ.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=occ.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/orthocell-ltd-</span><span class="invisible">177-occ.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=occ.asx</span></a></p>
US News in English<p>Incannex completes Phase 2 enrollment in global RePOSA study for sleep apne... - published 03 Apr 2025 <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/ltd" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ltd</span></a> <a href="https://mastodon-grafa.social/tags/Grafa" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Grafa</span></a> <a href="https://mastodon-grafa.social/tags/Nasdaq" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Nasdaq</span></a> <a href="https://mastodon-grafa.social/tags/HealthCare" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>HealthCare</span></a> <br><a href="https://grafa.com/news/health-incannex-completes-phase-2-enrollment-in-global-reposa-study-for-sleep-apnea-treatment-414183?utm_source=us_news_en&utm_medium=mastodon&utm_campaign=414183" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/news/health-incannex</span><span class="invisible">-completes-phase-2-enrollment-in-global-reposa-study-for-sleep-apnea-treatment-414183?utm_source=us_news_en&utm_medium=mastodon&utm_campaign=414183</span></a></p>
ASX Mkt. Sensitive<p>Orthocell ( <a href="https://mastodon-grafa.social/tags/OCC" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>OCC</span></a> ) has released " Trading Halt " on Thu 03 Apr at 09:06 AEST <a href="https://mastodon-grafa.social/tags/trading" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>trading</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/Strategy" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Strategy</span></a> <br><a href="https://grafa.com/asset/orthocell-ltd-177-occ.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=occ.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/orthocell-ltd-</span><span class="invisible">177-occ.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=occ.asx</span></a></p>
ASX Mkt. Sensitive<p>Race Oncology ( <a href="https://mastodon-grafa.social/tags/RAC" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>RAC</span></a> ) has released " RC220 Phase 1 Trial Opens for Patient Enrolment " on Thu 03 Apr at 08:57 AEST <a href="https://mastodon-grafa.social/tags/UnitedStates" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>UnitedStates</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/live" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>live</span></a> <br><a href="https://grafa.com/asset/race-oncology-ltd-3890-rac.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=rac.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/race-oncology-</span><span class="invisible">ltd-3890-rac.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=rac.asx</span></a></p>
ASX Mkt. Sensitive<p>Bioxyne ( <a href="https://mastodon-grafa.social/tags/BXN" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>BXN</span></a> ) has released " BXN Signs Exclusive $7m Manufacturing and Supply Agreement " on Thu 03 Apr at 08:32 AEST <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/live" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>live</span></a> <a href="https://mastodon-grafa.social/tags/ltd" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ltd</span></a> <br><a href="https://grafa.com/asset/bioxyne-ltd-6076-bxn.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=bxn.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/bioxyne-ltd-60</span><span class="invisible">76-bxn.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=bxn.asx</span></a></p>
ASX Mkt. Sensitive<p>Opthea ( <a href="https://mastodon-grafa.social/tags/OPT" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>OPT</span></a> ) has released " Opthea Announces Decision to Discontinue Wet AMD Trials " on Mon 31 Mar at 12:41 AEST <a href="https://mastodon-grafa.social/tags/today" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>today</span></a> <a href="https://mastodon-grafa.social/tags/trading" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>trading</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <br><a href="https://grafa.com/asset/opthea-ltd-3521-opt.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=opt.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/opthea-ltd-352</span><span class="invisible">1-opt.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=opt.asx</span></a></p>
ASX Mkt. Sensitive<p>Mesoblast ( <a href="https://mastodon-grafa.social/tags/MSB" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>MSB</span></a> ) has released " First Children To Begin Treatment, Medicaid Covers Ryoncil " on Mon 31 Mar at 09:59 AEST <a href="https://mastodon-grafa.social/tags/today" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>today</span></a> <a href="https://mastodon-grafa.social/tags/government" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>government</span></a> <a href="https://mastodon-grafa.social/tags/China" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>China</span></a> <a href="https://mastodon-grafa.social/tags/UnitedStates" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>UnitedStates</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <br><a href="https://grafa.com/asset/mesoblast-ltd-3198-msb.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=msb.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/mesoblast-ltd-</span><span class="invisible">3198-msb.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=msb.asx</span></a></p>
ASX Mkt. Sensitive<p>Nyrada ( <a href="https://mastodon-grafa.social/tags/NYR" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>NYR</span></a> ) has released " First Cohort Dosed in Nyradas Phase I Clinical Trial " on Mon 31 Mar at 09:52 AEST <a href="https://mastodon-grafa.social/tags/today" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>today</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/live" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>live</span></a> <br><a href="https://grafa.com/asset/nyrada-inc-3430-nyr.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=nyr.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/nyrada-inc-343</span><span class="invisible">0-nyr.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=nyr.asx</span></a></p>
ExploreLive feeds
Mastodon is the best way to keep up with what's happening.
Follow anyone across the fediverse and see it all in chronological order. No algorithms, ads, or clickbait in sight.
Create accountLoginDrag & drop to upload